{"entity":{"id":"idea-tr1-just-in-time-site-network","kind":"idea","name":"Just-in-time site activation: open a site in two weeks when a patient appears","aka":[],"tldr":"Instead of opening a trial at fifty hospitals and waiting for patients, keep a network of pre-vetted clinics ready and switch a trial on where a matching patient is found.","summary":"A network of community and academic sites holds master agreements, a central IRB, standing budgets and trained staff; when a matched patient is identified (via matching tools or referral), the site is activated for that protocol within 10-14 days. TAPUR and some rare-tumour and biomarker-defined trials have used this model; the idea is to make it the default for biomarker-selected phase 2 and rare-cancer trials and to fund the network as infrastructure.","asOf":"2026-09-08","links":[{"label":"ASCO TAPUR Study","url":"https://www.tapur.org/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":["asco"],"pathways":[],"terms":["basket-umbrella-platform"],"trials":[],"people":[],"bottlenecks":["b-trial-enrolment","b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Biomarker-selected trials run through a just-in-time network will reach target accrual in less than half the calendar time of conventional site selection and at lower cost per enrolled patient, because idle-site costs are removed.","rationale":"In conventional trials a large share of opened sites enrol zero or one patient, while eligible patients at non-participating sites are never enrolled. JIT inverts the logic: capacity follows the patient.","test":"Run two similar biomarker-selected phase 2 studies from one sponsor, one via JIT network and one via conventional site selection, and compare time to accrual, cost per patient and geographic spread of enrolled patients.","maturity":"early-clinical","actor":"industry","cost":"medium","horizonYears":2},"route":"/ideas/idea-tr1-just-in-time-site-network/","neighbours":{"technology":[{"id":"ai-trial-matching","kind":"technology","name":"AI trial matching & clinical decision support","route":"/technologies/ai-trial-matching/"}],"institution":[{"id":"asco","kind":"institution","name":"American Society of Clinical Oncology (ASCO)","route":"/institutions/asco/"}],"term":[{"id":"basket-umbrella-platform","kind":"term","name":"Basket, umbrella, and platform trials","route":"/terms/basket-umbrella-platform/"}],"bottleneck":[{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"},{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/"}]}}